- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT06659549
Une étude de phase 2 sur l'efficacité et l'innocuité du GAL-101, solution ophtalmique à 2 % dans l'atrophie géographique non fovéale secondaire à la DMLA non néovasculaire (eDREAM)
Une étude de phase 2, en double insu, randomisée, multicentrique, en groupes parallèles, contrôlée par placebo, pour étudier l'efficacité et l'innocuité de la solution ophtalmique GAL-101, 2 %, chez les patients présentant une atrophie géographique non fovéale secondaire à un âge non néovasculaire. Dégénérescence maculaire associée : étude EDREAM
Age-related macular degeneration (AMD) affects millions of elderly patients. When advanced, there is Geographic Atrophy (GA) in the retina. This means that there is an area with a loss of light-sensitive cells, called photoreceptors. That part of the retina can no longer see. Atrophy begins as a small spot in the retina distant from the fovea which is the part of the retina responsible for sharp central vision. The GA grows, and when it reaches the fovea, vision is severely diminished, and details cannot be seen anymore. The purpose of the eDREAM study is to understand if GAL-101 can slow the growth of GA and prevent it from reaching the fovea. GAL-101 is given as eyedrops. eDREAM patients will administer study eyedrops every day. Patients will be assigned by chance (randomly) to receive either eye-drops that contain the new medication, GAL-101, or eyedrops without the active drug (Placebo). Neither patients nor doctors will know which treatment was assigned to each patient until the end of the study.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
In this study, if both eyes qualify for the study, the eye with the better BCVA will be defined as the study eye. If both eyes qualify for the study and have identical BCVA, then the eye with higher baseline peripheral retinal degenerations (PRD) will be defined as the study eye. If baseline PRD is identical, then the right eye (OD) will be defined as the study eye. Only the study eye will be dosed with the Investigation Medicinal Product (IMP).
During visits, patients will administer 3 applications of 1 drop of GAL-101 or a matching Placebo that does not contain the active pharmaceutical ingredient (API) at 5-minute intervals (i.e., 1st application, wait 5 minutes, 2nd application, wait 5 minutes, 3rd application), under the supervision of trained and authorized study personnel. In between visits, patients will be instructed to administer 2 applications of 1 drop at 5-minute intervals once a day.
The study will be comprised of a 12- to 24-month treatment period determined individually according to patients' overall placement in global study randomization. All patients will participate at least 12 months of treatment. The visit schedule includes the following: Screening visits (Visit 1a and 1b) for image capture and confirmation of study eligibility by a reading center; Baseline/Randomization/Day 1 (Visit 2); a phone call at 2 weeks; and on-treatment clinic visits for safety and efficacy evaluations at 1 month, 3 months, 6 months, 9 months, and 12 months. Patients will continue to attend on-treatment clinic visits at 3-month intervals after 12 months until the last patient randomized in the study has completed 12 months of study treatment.
Type d'étude
Inscription (Estimé)
Phase
- Phase 2
Contacts et emplacements
Coordonnées de l'étude
- Nom: Galimedix Inc. c/o Imperial CRS, MD
- Numéro de téléphone: +1 (301) 9179191
- E-mail: info@galimedix.com
Sauvegarde des contacts de l'étude
- Nom: Luciana Summo, PhD
- E-mail: info@galimedix.com
Lieux d'étude
-
-
-
Bonn, Allemagne, 53127
- Recrutement
- Universitäts-Augenklinik Bonn
-
Chercheur principal:
- Kristina Pfau, MD
-
Contact:
- Joanna Czauderna Study Coordinator
- Numéro de téléphone: 0228 287-11493
- E-mail: Joanna.Czauderna@ukbonn.de
-
Freiburg im Breisgau, Allemagne, 79106
- Recrutement
- Universitätsklinikum Freiburg Klinik für Augenheilkunde
-
Chercheur principal:
- Hansjuergen Agostini, MD
-
Contact:
- Christine Kremer
- Numéro de téléphone: +49 761 270 40231
- E-mail: christine.kremer@uniklinik-freiburg.de
-
Hanover, Allemagne, 30625
- Recrutement
- Medizinische Hochschule Hannover Augenklinik
-
Contact:
- Irene Oluwatoba-Popoola
- E-mail: Oluwatoba-popoola.irene@mh-hannover.de
-
Chercheur principal:
- Ekaterina Sokolenko, MD
-
Neubrandenburg, Allemagne, 17036
- Recrutement
- Dietrich Bonhoeffer Klinikum
-
Contact:
- Ulrike Holland
- Numéro de téléphone: +49 395 775 13427
- E-mail: aug-st2@dbknb.de
-
Chercheur principal:
- Christian Brinkmann, MD
-
Tübingen, Allemagne, 72076
- Recrutement
- Universitätsklinikum Tübingen, Department für Augenheilkunde.
-
Contact:
- Angela Geiger
- E-mail: Felix.Reichel@med.uni-tuebingen.de
-
Chercheur principal:
- Felix Reichel, MD
-
Ulm, Allemagne, 89075
- Pas encore de recrutement
- UNIVERSITÄTSKLINIKUM ULM Klinik für Augenheilkunde
-
Contact:
- Julia Ciboci
- E-mail: Julia.Ciboci@uniklinik-ulm.de
-
Chercheur principal:
- Armin Wolf, MD
-
-
-
-
-
Yerevan, Arménie, 0048
- Recrutement
- Ophthalmological Center After S.V. Malayan
-
Contact:
- Ani Babayan
- Numéro de téléphone: +37494909990
- E-mail: babayanani88@yahoo.com
-
Chercheur principal:
- Lilit Voskanyan, MD, PhD
-
-
-
-
-
Bordeaux, France, 33000
- Recrutement
- Centre Rétine Gallien
-
Contact:
- Manon Demeurs
- Numéro de téléphone: 33 (5) 56 11 32 25
- E-mail: arc@retinegallien.com
-
Chercheur principal:
- Eric Fourmaux, MD
-
Lyon, France, 69317
- Recrutement
- Hopital de La Croix-Rousse Service D'Ophtalmologie Groupement Hospitalier Nord Hospices Civils de Lyon
-
Contact:
- Roxane Bai
- Numéro de téléphone: +33 (0)4 26 73 27 02
- E-mail: roxane.bai@chu-lyon.fr
-
Chercheur principal:
- Laurent KODJIKIAN, MD
-
Marseille, France, 13008
- Recrutement
- Centre Monticelli Paradis d'Ophtalmologie
-
Contact:
- Agné Devin Dr.
- Numéro de téléphone: 049116 05 84
- E-mail: agne.retine@gmail.com
-
Chercheur principal:
- François Devin, MD
-
Paris, France, 75006
- Recrutement
- Centre Ophtalmologique Odéon
-
Contact:
- Sumeyye OZALTUN
- E-mail: ozalt.sumeyye@gmail.com
-
Contact:
- Favard, MD
-
Chercheur principal:
- Catherine Favard, MD
-
Tours, France, 37540
- Recrutement
- Centre médico-chirurgical de Touraine
-
Contact:
- Sarah Van Herreweghe
- Numéro de téléphone: 33 (0)2 47 64 67 27
- E-mail: svanherreweghe6@gmail.com
-
Chercheur principal:
- Sam Razavi, MD
-
-
-
-
-
Tbilisi, Géorgie, 0162
- Recrutement
- Akhali Mzera Limited
-
Contact:
- Revaz Bezarashvili
- Numéro de téléphone: (+995) 555 55 54 82
- E-mail: rezieye@gmail.com
-
Chercheur principal:
- Shalva Skhirtladze, MD
-
Tbilisi, Géorgie, 0186
- Recrutement
- Caucasus Medical Centre LLC
-
Contact:
- Sopio Tsiklauri, MD
- Numéro de téléphone: (+995) 595 974 774
- E-mail: soffia01@yahoo.com
-
Chercheur principal:
- Mikheil Omiadze, MD, PhD
-
-
-
-
-
Kildare, Irlande, W91 W535
- Recrutement
- UPMC Kildare Hospital Prosperous Rd Clane, Kildare Ireland
-
Chercheur principal:
- Eugene Ng, MD
-
Contact:
- Hiella Akhundova
- Numéro de téléphone: +353 89 411 2119
- E-mail: hiella.a@ioes.ie
-
Waterford, Irlande, X91 DH9W
- Recrutement
- Institute of Eye Surgery (IOES Waterford)
-
Chercheur principal:
- Eugene Ng, MD
-
Contact:
- Emmanuel Ankamah
- Numéro de téléphone: +353 89 411 2119
- E-mail: emmanuel.a@ioes.ie
-
-
-
-
-
Jerusalem, Israël, 9112001
- Recrutement
- Hadassah Medical Center
-
Contact:
- Michal Shpigel
- Numéro de téléphone: 972-54-4575921
- E-mail: smichal@hadassah.org.il
-
Chercheur principal:
- Tareq Jaouni, MD
-
Tel Aviv, Israël, 6423906
- Recrutement
- Tel Aviv Medical Center
-
Contact:
- Marina Gordon
- Numéro de téléphone: 972-3-6947371
- E-mail: marinago@tlvmc.gov.il
-
Chercheur principal:
- Omer Trivizki, MD
-
-
-
-
Milano
-
Milan, Milano, Italie, 20123
- Recrutement
- Medical Retina & Imaging Unit, IRCCS MultiMedica, Ospedale San Giuseppe
-
Contact:
- Mara Cattaneo Study Coordinator
- E-mail: mara.cattaneo@multimedica.it
-
Chercheur principal:
- Stela Vujosevic, MD
-
Milan, Milano, Italie, 20132
- Recrutement
- Unità di Oculistica, IRCCS Ospedale San Raffaele
-
Contact:
- Adelaide Pina Study Coordinator
- Numéro de téléphone: 0226433545
- E-mail: pina.adelaide@hsr.it
-
Chercheur principal:
- Francesco Bandello, MD
-
-
Roma
-
Roma, Roma, Italie, 00184
- Recrutement
- UOS Retina Medica, P.O. Britannico, IRCCS Fondazione G.B. Bietti per lo Studio e la Ricerca in Oftalmologia
-
Contact:
- Ilaria Casale, Dr
- E-mail: ilaria.casale@fondazionebietti.it
-
Chercheur principal:
- Mariacristina Parravanno, MD
-
-
-
-
California
-
Beverly Hills, California, États-Unis, 90211
- Recrutement
- Retina-Vitreous Associates Medical Group
-
Chercheur principal:
- David Boyer, MD
-
Contact:
- Rahul Araza
- Numéro de téléphone: 3 (310) 289-2478
- E-mail: raraza@laretina.com
-
Walnut Creek, California, États-Unis, 94598
- Recrutement
- Bay Area Retina Associates
-
Chercheur principal:
- Roger Goldberg, MD
-
Contact:
- Karrie Padilla
- Numéro de téléphone: 925-265-4146
- E-mail: kpadilla@bayarearetina.com
-
-
Maryland
-
Hagerstown, Maryland, États-Unis, 21740
- Suspendu
- Cumberland Valley Retina Consultants
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
-
≥55 years of age
-
Willing and able to provide written informed consent
-
Willing and able to comply with the study schedule and study assessments
-
Able to successfully administer ophthalmic solution or have an appropriate designee (e.g., family member, health care professional) who can administer ophthalmic solution
-
BCVA of ≥50 letters in the study eye using Early Treatment Diabetic Retinopathy Study (ETDRS) chart (i.e., 20/100 Snellen equivalent). Criterion will be confirmed at Baseline
-
Refractive error between +3 and -6 diopters spherical equivalent in the study eye
-
Sufficiently clear ocular media and adequate pupillary dilation to permit quality fundus imaging of the study eye, in the opinion of the Investigator. Criterion will be confirmed at Baseline
-
Diagnosed with non-foveal GA secondary to non-neovascular AMD in the study eye, as confirmed by the reading center
- Well-delineated cumulative GA area between 1.25 and 12.0 mm2
- If GA is multifocal, at least 1 lesion ≥1.25 mm2
- GA lesions must be located outside a ≥100 µm radius from the center point of the fovea (i.e., this area must have intact retinal pigment epithelium [RPE] and outer retina)
- GA lesions must be located (partially or wholly) within a 2000 µm radius from the center point of the fovea
- GA lesions must be completely located within FAF imaging field (field 2 to 30-degree image centered on the fovea). GA lesion borders must be >300 µm from image edges
- GA lesions must be >300 µm from the optic disc and/or peripapillary atrophy
- Area of PRD must be cumulatively between 7.25 and 25.0 mm2
Exclusion Criteria:
-
Presence or history of choroidal neovascularization (CNV). Criterion will be confirmed at Baseline
-
History of laser therapy in the macular region, regardless of indication
-
History of herpes zoster
-
Ophthalmic disease or condition that requires or is likely to require surgery during the study period
-
GA with cumulative area <1.25 mm2
-
Any GA lesion within 100 µm radius from the center point of the fovea
-
Axial length >26 mm
-
Any ocular disease or condition other than non-neovascular AMD that may, in the opinion of the Investigator, interfere with study assessments, patient adherence to the study schedule, or interpretation of study data (e.g., epiretinal membrane, macular hole, glaucomatous optic neuropathy, etc.)
-
Intraocular surgery (including cataract extraction and crystalline lens replacement) within 3 months before Visit 1a or yttrium aluminum garnet (YAG) surgery within 2 months before Visit 1a, or planned either during the study period
-
Use of pegcetacoplan or avacincaptad pegol within 6 months before Visit 1a, or planned use during the study period
-
Use of any prescription or over-the-counter ophthalmic medication within 1 month before Visit 1a or planned use during the study period
-
Use of rigid contact lenses within 1 month before Visit 1a or planned use during the study period
Non-study Eye:
-
BCVA of <5 letters using ETDRS chart (i.e., 20/800 Snellen equivalent)
Either Eye:
-
History of uveitis
-
GA secondary to any condition other than non-neovascular AMD
-
History of active ocular infection or inflammation within 3 months before Visit 1a or Baseline. Criterion will be confirmed at Baseline
-
Underwent investigational treatment for AMD within 6 months before Visit 1a
General Exclusion Criteria:
-
History of therapeutic radiation to the cranium
-
Known allergy or hypersensitivity to the investigational medicinal product (IMP) or any of its excipients
-
History of malignant disease
-
Use of hydroxychloroquine within 1 month before Visit 1a, or planned use during the study period
-
Participated or plan to participate in any other IMP study within 1 month before Visit 1a or during the study period
-
Use of lutein >10 mg per day or zeaxanthin >2 mg per day within 1 month before Visit 1a, or planned use during the study period
-
Any medical condition (including mental), in the opinion of the Investigator, that could interfere with study assessments, patient adherence to the study schedule, or interpretation of study data
-
Screening laboratory values, in the opinion of the Investigator, that make the patient unsuitable for study participation
-
Pregnant, nursing, or planning a pregnancy during the study. Criterion will be confirmed at Baseline
-
Unwilling or unable to use an acceptable method of contraception throughout the study if a woman of childbearing potential (WOCBP) or if a sexual partner of a WOCBP
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Quadruple
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: GAL-101 ophthalmic solution
Patient will apply daily 2 eye drops of GAL-101 at 5 minutes interval |
Patient will apply daily 2 eye drops of GAL-101 at 5 minutes interval |
|
Comparateur placebo: Placebo
Patient will apply daily 2 eye drops ofPlacebo at 5 minutes interval |
Patient will apply daily 2 eye drops of Placebo at 5 minutes interval |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Efficacy of GAL-101 ophthalmic solution in reducing the rate of change in GA lesion size.
Délai: From baseline to last on-treatment visit (48 up to 96 weeks)
|
Comparison between groups of annual rate of change in the area of GA as measured by fundus autofluorescence (FAF). |
From baseline to last on-treatment visit (48 up to 96 weeks)
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Efficacy of GAL-101 ophthalmic solution in reducing the rate of change in photoreceptor degeneration (PRD) in eyes with GA
Délai: From baseline to last on-treatment visit (48 up to 96 weeks)
|
Comparison between groups of annual rate of change in the area of PRD as measured by optical coherence tomography (OCT) |
From baseline to last on-treatment visit (48 up to 96 weeks)
|
Collaborateurs et enquêteurs
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- GAL-101-C0201
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .